Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment.
Tan-Trieu NguyenLeeAnn RamsayMozhdeh Ahanfeshar-AdamsMathieu LajoieDirk SchadendorfTommy AlainIan R WatsonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
We provide mechanistic support for the use of OVs as a precision medicine strategy for both salvage therapy in ICI-resistant and first-line treatment in melanomas with IFNγ-JAK-STAT pathway mutations. Our study also supports JAK inhibitor-OV combination therapy for treatment-naïve melanomas without IFN signaling defects.See related commentary by Kaufman, p. 3278.